Zealand Pharma AS (Zealand) is a biotechnology company that discovers and develops peptide-based medicines. The company's pipeline products include liraglutide, a long-acting GLP-2 analog in development for the treatment of short bowel syndrome; dasiglucagon for congenital hyperinsulinism and bi-hormonal artificial pancreas systems; survodutide (BI 456906) treats obesity and nonalcoholic steatohepatitis; ZP8396 for overweight and obesity; dapiglutide for obesity. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. Zealand is headquartered in Soeborg, Denmark.
Zealand Pharma AS premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Glepaglutide: Short Bowel Syndrome |
Dasiglucagon: |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Financing Agreements | In December, the company signed a finance agreement with the European Investment Bank to secure a loan facility of EUR90 million. |
2023 | Others | In June, the company announced the submission of a new drug application to the US Food and Drug Administration (FDA) for dasiglucagon for the prevention and treatment of low blood sugar (hypoglycemia) in pediatric patients 7 days of age or older with congenital hyperinsulinism. |
2022 | Contracts/Agreements | In September, the company entered into a global license and development agreement with Novo Nordisk to commercialize ZEGALOGUE (dasiglucagon) for injection. |
Competitor Comparison
Key Parameters | Zealand Pharma AS | Bavarian Nordic AS | Ascendis Pharma AS | Cyclenium Pharma Inc | Forward Pharma AS |
---|---|---|---|---|---|
Headquarters | Denmark | Denmark | Denmark | Canada | Denmark |
City | Soeborg | Hellerup | Hellerup | Montreal | Hellerup |
State/Province | - | - | - | Quebec | - |
No. of Employees | 253 | 1,379 | 879 | - | - |
Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Martin Nicklasson | Chairman | Executive Board | 2015 | 68 |
Kirsten A. Drejer | Vice Chairman | Executive Board | 2018 | 67 |
Adam Steensberg | Chief Executive Officer; President | Senior Management | 2022 | 49 |
Henriette Wennicke | Chief Financial Officer; Executive Vice President | Senior Management | 2022 | 40 |
Ivan Moller | Chief Operating Officer; Executive Vice President | Senior Management | 2018 | 51 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer